Introduction: The Economic Burden of Gestational Diabetes

Gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy, affecting approximately 7–14% of pregnancies globally, with rates rising in parallel with the obesity epidemic. While the clinical imperative to screen and treat GDM is well established — reducing risks of macrosomia, preeclampsia, and neonatal hypoglycemia — the economic implications of widespread screening programs are less frequently examined. Healthcare systems must weigh the short-term costs of universal testing and follow-up against the long-term savings from preventing severe maternal and neonatal complications. This article provides a comprehensive analysis of how GDM screening influences healthcare costs and resource allocation, and offers evidence-based strategies for optimizing expenditure without compromising quality of care.

Epidemiology and Rising Prevalence of GDM

The prevalence of GDM has increased dramatically over the past two decades, driven by rising maternal age, higher rates of obesity, and changes in diagnostic criteria. According to the World Health Organization, hyperglycemia in pregnancy accounts for an estimated 20 million live births annually. The adoption of the International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria in many countries has also led to a doubling of GDM diagnoses. This epidemiological shift means that screening programs now cast a wider net, capturing milder cases that carry their own economic implications. Understanding population-specific prevalence rates is essential for projecting screening costs and planning resource allocation accordingly.

GDM Screening Methods: From Glucose Challenge to OGTT

Most guidelines recommend screening at 24–28 weeks of gestation using either a one-step or two-step approach. The one-step method involves a 75-gram oral glucose tolerance test (OGTT) with fasting, one-hour, and two-hour glucose measurements. The two-step method begins with a 50-gram glucose challenge test (GCT) and, if abnormal, proceeds to a diagnostic 100-gram OGTT. Both approaches have distinct cost profiles. The one-step method reduces missed diagnoses but requires more reagents and laboratory time, while the two-step method may lower initial testing costs but can lead to additional follow-up visits. Newer alternatives such as fasting blood glucose and hemoglobin A1c (HbA1c) have been proposed but lack sufficient sensitivity for universal screening. The choice of screening strategy directly impacts both direct costs and the downstream resource burden on antenatal care systems.

Direct and Indirect Costs of GDM Screening

Upfront Screening Costs

The immediate costs of implementing universal GDM screening include test materials, laboratory processing, provider time for counseling, and additional patient visits for diagnostic confirmation. In high-income countries, the cost per screen ranges from $15 to $50 for a GCT, and $50 to $150 for a full OGTT, depending on facility overhead and labor rates. For a population of 4 million annual births in the United States, universal one-step screening could add over $600 million in direct laboratory costs alone. These figures do not include the infrastructure needed to manage increased clinic throughput: additional nursing staff, registration personnel, and extended clinic hours. In settings where screening is already integrated into routine prenatal care, incremental costs may be lower, but they remain a significant line item for healthcare budgets.

Long-Term Savings from Early Detection

Though upfront costs are substantial, they must be offset against the avoided costs of GDM-related complications. Undiagnosed or poorly managed GDM is associated with higher rates of cesarean delivery, preeclampsia, shoulder dystocia, and neonatal intensive care unit (NICU) admissions. A single NICU stay for a macrosomic infant can exceed $50,000, while the cost of treating preeclampsia — including antihypertensive therapy, monitoring, and possible early delivery — easily surpasses $10,000. Multiple cost-effectiveness analyses have demonstrated that universal screening reduces the incidence of these adverse outcomes by 30–50%, yielding net savings of $1,500–$3,000 per screened pregnancy over the first year postpartum. When the long-term metabolic risk to the mother — who has a 50% chance of developing type 2 diabetes within 10 years — is factored in, the economic case becomes even stronger. Early intervention through lifestyle counseling and postpartum glucose testing can delay or prevent diabetes, sparing healthcare systems tens of thousands of dollars per patient over a lifetime.

Resource Allocation in Diverse Healthcare Settings

Workforce and Laboratory Demands

Screening all pregnant women places considerable strain on healthcare infrastructure, particularly on laboratory capacity. OGTTs require precise timing, trained phlebotomists, and reliable glucose analyzers. In busy obstetric clinics, the need for multiple blood draws over two to three hours can back up appointments and reduce overall clinic efficiency. Moreover, borderline screening results generate additional follow-up visits for diagnostic testing and diabetes education. These tasks often fall to midwives, nurses, or nurse practitioners, who must also manage the rising demand for postpartum screening. The Centers for Disease Control and Prevention notes that over 50% of women with a history of GDM do not receive a postpartum glucose test, representing a missed opportunity for cost-effective prevention. To meet these demands, healthcare systems may need to invest in point-of-care glucose testing devices, telemedicine counseling, and dedicated diabetes care coordinators — all of which require upfront capital but can streamline workflow over time.

Challenges in Low-Resource Environments

In low- and middle-income countries (LMICs), where nearly 90% of GDM cases occur, resource constraints are severe. Laboratory facilities may be located far from rural clinics, and basic supplies like glucose reagent strips can be in short supply. The cost of a single OGTT may represent a significant portion of a family's monthly income, and follow-up care is often interrupted by transportation barriers. In these settings, universal screening can overwhelm existing maternal health services, diverting attention from other essential interventions such as management of infectious diseases or emergency obstetric care. Pilot programs in sub-Saharan Africa and South Asia have shown that targeted screening based on risk factors — age, body mass index (BMI), family history of diabetes, and previous GDM — can identify 60–80% of cases while using only 30–40% of the resources required for universal screening. However, risk-based approaches can also miss women with no identifiable risk factors, especially in populations where obesity is less prevalent. Policymakers in LMICs must therefore tailor screening strategies to local epidemiology and resource availability, often relying on cheaper tests like fasting plasma glucose in combination with risk scoring.

Targeted Versus Universal Screening: Balancing Efficiency and Equity

The debate between universal and targeted screening is central to cost and resource discussions. Proponents of universal screening argue that it captures all cases, prevents avoidable complications, and aligns with principles of equity — every pregnant woman deserves the same standard of care. Critics point to the high number needed to screen (NNS) to prevent one adverse outcome: for GDM, the NNS is approximately 20–25 for preventing macrosomia and 40–50 for preventing preeclampsia. In universal programs, many women receive testing and follow-up who would never have developed complications, inflating costs without proportional benefit. A landmark trial published in the New England Journal of Medicine compared universal and selective screening and found that while universal screening detected more GDM cases, perinatal outcomes were not significantly different between groups — a result that has intensified the cost-effectiveness debate. The optimal approach may be a hybrid model: universal initial screening using a low-cost, low-burden test (e.g., fasting glucose) combined with risk-based selective use of OGTT for borderline results. Such stepwise strategies can reduce total testing costs by 30–50% while maintaining detection rates above 90%.

Strategies for Optimizing Resource Use

Healthcare systems can adopt several evidence-based strategies to maximize the value of GDM screening investments:

  • Risk-stratified screening algorithms: Use maternal age, BMI, prior GDM, and family history to assign screening pathways. Low-risk women may receive a single fasting glucose test, while high-risk women undergo a full OGTT. This can reduce per-patient costs by 25–40% without missing a significant number of cases.
  • Point-of-care testing: Portable glucose analyzers enable immediate results in clinic settings, reducing follow-up visits and lab turnaround times. Although per-test costs may be slightly higher, they free up central laboratory capacity and improve patient retention.
  • Group prenatal care for GDM: Cluster women with GDM into group education sessions for diet and glucose monitoring, reducing the need for individual appointments. Studies show this model reduces provider time by 50% while achieving glycemic outcomes comparable to individual care.
  • Telehealth for follow-up: Remote blood glucose monitoring via smartphone apps or text messaging can replace in-person visits for many women with well-controlled GDM. This cuts travel costs and clinic congestion.
  • Training non-specialist providers: In LMICs, task-shifting diabetes education and basic management to midwives and community health workers lowers the burden on obstetricians and expands coverage without increasing total personnel costs.

Implementing these strategies requires initial investment in protocol development, training, and technology, but the return on investment is typically realized within one to two years through reduced complication rates and streamlined care.

Policy Implications and Future Directions

Health policymakers face the challenge of designing screening programs that are both clinically effective and fiscally sustainable. The cost of GDM screening must be viewed in the context of the overall maternal health budget. For example, a 2019 analysis from the UK National Health Service found that universal OGTT screening added roughly £200 per pregnancy but saved £900 in avoided complications — a net benefit of £700 per woman screened. However, these savings depend on robust postpartum follow-up, and many health systems lack the integrated data systems to track long-term outcomes. To improve resource allocation, governments should:

  • Fund prospective cost-effectiveness studies that account for local demographics and infrastructure.
  • Establish national GDM registries to monitor screening coverage, treatment outcomes, and downstream costs.
  • Invest in scalable digital tools for glucose monitoring and patient education.
  • Negotiate bulk pricing for glucose test supplies and point-of-care devices.
  • Integrate GDM screening with other antenatal interventions (e.g., syphilis screening, anemia testing) to share fixed costs.

Looking forward, advances in non-invasive screening (e.g., continuous glucose monitors) and risk-prediction models using artificial intelligence could further reduce costs and improve precision. For example, machine learning algorithms that incorporate electronic health record data may identify women who would benefit most from OGTT, minimizing unnecessary testing. The economic impact of such innovations should be rigorously evaluated before widespread adoption.

Conclusion

GDM screening imposes undeniable upfront costs on healthcare systems, including laboratory tests, provider time, and follow-up resources. Yet the weight of evidence indicates that these investments yield substantial long-term savings by preventing expensive complications like cesarean deliveries, NICU admissions, and later-life type 2 diabetes. The challenge lies not in whether to screen, but in how to screen efficiently and equitably. Risk-targeted strategies, point-of-care technology, and task-shifting can stretch limited resources, while universal programs in higher-resource settings remain defensible when backed by robust cost-effectiveness data. Policymakers must continue to adapt screening protocols to local epidemiologic and economic realities, ensuring that every pregnant woman receives the care she needs without bankrupting the system that provides it. With thoughtful planning and ongoing evaluation, GDM screening can be both a clinical success and a sound financial decision.